XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Goodwill and other intangible assets, net | 9 Months Ended
--- | ---
Sep. 25, 2016
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and other intangible assets, net | Note 6 — Goodwill and other intangible assets, net The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the nine months ended September 25, 2016:
| Vascular North America |  | Anesthesia North America |  | Surgical North America |  | EMEA |  | Asia |  | OEM |  | All Other |  | Total
| (Dollars in thousands)
Balance as of December 31, 2015 | $ | 345,546 |  |  | $ | 141,122 |  |  | $ | 250,912 |  |  | $ | 306,009 |  |  | $ | 141,067 |  |  | $ | 1,194 |  |  | $ | 110,002 |  |  | $ | 1,295,852 |
Goodwill related to acquisitions | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3,947 |  |  | — |  |  | 3,947 |
Currency translation adjustment | — |  |  | 318 |  |  | — |  |  | 1,363 |  |  | 6,729 |  |  | — |  |  | (3,131 | ) |  | 5,279 |
Balance as of September 25, 2016 | $ | 345,546 |  |  | $ | 141,440 |  |  | $ | 250,912 |  |  | $ | 307,372 |  |  | $ | 147,796 |  |  | $ | 5,141 |  |  | $ | 106,871 |  |  | $ | 1,305,078 |
The following table provides information as of September 25, 2016 and December 31, 2015 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net:
| Gross Carrying Amount |  | Accumulated Amortization
| September 25, 2016 |  | December 31, 2015 |  | September 25, 2016 |  | December 31, 2015
| (Dollars in thousands)
Customer relationships | $ | 630,127 |  |  | $ | 621,078 |  |  | $ | (235,074 | ) |  | $ | (214,924 | )
In-process research and development | 58,668 |  |  | 58,908 |  |  | — |  |  | — |
Intellectual property | 523,361 |  |  | 522,374 |  |  | (197,465 | ) |  | (173,903 | )
Distribution rights | 23,356 |  |  | 23,279 |  |  | (15,294 | ) |  | (14,393 | )
Trade names | 387,759 |  |  | 384,821 |  |  | (12,734 | ) |  | (8,929 | )
Non-compete agreements | 2,853 |  |  | 2,186 |  |  | (913 | ) |  | (522 | )
| $ | 1,626,124 |  |  | $ | 1,612,646 |  |  | $ | (461,480 | ) |  | $ | (412,671 | )
In May 2012, the Company acquired Semprus BioSciences Corp. ("Semprus"), a biomedical research and development company that developed a polymer surface treatment technology intended to reduce thrombus related complications. As previously disclosed, the Company experienced difficulties with respect to the development of the Semprus technology, and devoted further research and testing towards attempting to resolve the issue. As a result of these efforts, the Company believes it has resolved the issue and is focused on seeking regulatory approval and engaging in additional research and development efforts to achieve commercialization of the technology. Despite the progress made since these issues were first identified, significant challenges to commercialization of the Semprus technology remain, and the Company ultimately may find it necessary to recognize impairment charges with respect to the related assets, which could be material. As of September 25, 2016, the Company has in-process research and development intangible assets of $41.0 million related to this investment, which is recorded in intangible assets, net. Amortization expense related to intangible assets was $16.1 million and $15.5 million for the three months ended September 25, 2016 and September 27, 2015, respectively, and $47.5 million and $45.3 million for the nine months ended September 25, 2016 and September 27, 2015, respectively.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration